General
Preferred name
TIPIRACIL
Synonyms
TIPIRACIL HYDROCHLORIDE ()
MA-1 hydrochloride ()
Tipiracil (hydrochloride) ()
Tipiracil hydrochloride component of lonsurf ()
Tipiracil hydrochloride component of s-95005 ()
TAS-1-462 ()
Tipiracil hydrochloride component of tas-102 ()
TPI ()
TPI (freebase) ()
MA-1 ()
Tipiracilo ()
P&D ID
PD007805
CAS
183204-72-0
183204-74-2
Tags
available
drug
Approved by
PMDA
FDA
First approval
2014
2015
Drug Status
approved
investigational
Max Phase
4.0
Drug indication
Cholangiocarcinoma
colorectal adenocarcinoma
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
45
DESCRIPTION
Tipracil inhibits thymidine phosphorylase (TYMP, P19971; a.k.a. platelet-derived endothelial cell growth factor), an enzyme which metabolises trifluridine.
TAS-102 contains tipracil as the hydrochloride salt (PubChem CID 9903778).
TAS-102 contains tipracil as the hydrochloride salt (PubChem CID 9903778).
DESCRIPTION
Tipracil is a a uracil derivative that inhibits thymidine phosphorylase (TYMP, P19971; a.k.a. platelet-derived endothelial cell growth factor), an enzyme which metabolises trifluridine.
TAS-102 contains tipracil as the hydrochloride salt (PubChem CID 9903778).
SARS-CoV-2: Tipracil has been shown to bind to the uridine-specific endoribonuclease Nsp15 of SARS-CoV-2, and this interaction inhibits the enzyme's uridine-degrading catalytic activity . (GtoPdb)
TAS-102 contains tipracil as the hydrochloride salt (PubChem CID 9903778).
SARS-CoV-2: Tipracil has been shown to bind to the uridine-specific endoribonuclease Nsp15 of SARS-CoV-2, and this interaction inhibits the enzyme's uridine-degrading catalytic activity . (GtoPdb)
DESCRIPTION
Tipiracil hydrochloride (MA-1 hydrochloride) is a thymidine phosphorylase inhibitor (TPI). Tipiracil hydrochloride is one of the active components in TAS-102, which is an anticancer drug candidate currently in clinical trials.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
22
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
59
Molecular Weight
242.06
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
3
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
1
cLogP
0.29
TPSA
92.81
Fraction CSP3
0.44
Chiral centers
0.0
Largest ring
6.0
QED
0.7
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Nucleoside antimetabolite/analog
Thymidylate Synthase
Phosphorylase,Thymidylate Synthase
Member status
member
MOA
Thymidine Phosphorylase Inhibitors
thymidine phosphorylase inhibitor
Indication
colorectal cancer
Pathway
Cell Cycle/DNA Damage
Apoptosis
Cell Cycle/Checkpoint
DNA Damage/DNA Repair
Source data
